Karyopharm Therapeutics’ Phase III XPORT-EC-042 trial assessing selinexor has failed to meet its primary endpoint of progression-free survival in patients with advanced or recurrent endometrial cancer with TP53 wild-type tumours.

The post Karyopharm’s XPORT-EC-042 study fails to meet primary endpoint appeared first on Clinical Trials Arena.